Datum Källa Rubrik Typ Alternativ
2023-07-24 Ziccum Ziccum säkrar andra Feasibility-avtalet på två månader: VD-intervju på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-20 Ziccum Ziccums Q2-rapport - VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-18 Ziccum ZICCUM AB (publ) Interim report Q2 2023 Rapporter Ladda ner | Visa Stäng
2023-07-17 Ziccum Ziccum signs Evaluation Agreement for Feasibility Study with major global Pharmaceutical Corporation Pressreleaser Ladda ner | Visa Stäng
2023-06-19 Ziccum Ziccum sponsors the Global mRNA-Based Therapeutics Summit, Boston MA, July 26-28 Pressreleaser Ladda ner | Visa Stäng
2023-06-05 Ziccum Ziccum joint proposal not selected for detailed application in current CEPI Call Pressreleaser Ladda ner | Visa Stäng
2023-06-02 Ziccum Ziccum appoints senior biopharma executive as new CFO Pressreleaser Ladda ner | Visa Stäng
2023-05-30 Ziccum Ziccum AB: BioStock Life Science Spring Summit med Ziccum Pressreleaser Visa Stäng
2023-05-30 Ziccum Ziccum AB: BioStock Life Science Spring Summit with Ziccum Pressreleaser Visa Stäng
2023-05-26 Ziccum Aerosol and inhalation authority Per Gerde joins Board of Directors of Ziccum AB Pressreleaser Ladda ner | Visa Stäng
2023-05-25 Ziccum Ziccum CEO to present at BioStock Life Science Spring Summit Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Ziccum Kommuniké från årsstämma i Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Ziccum Bulletin from the Annual General Meeting of Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 24 May 2023 | Ziccum

Bulletin from the Annual General Meeting of Ziccum AB (publ)

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Ziccum AB (publ) (“the Company”) on the 24th of May 2023 in Lund.

Adoption of income statement and balance sheet and discharge from liability
The AGM resolved to adopt the income statement for the financial year 2022 as well as the balance sheet as of 31 December 2022. The members of the Board of Directors and the managing director were discharged from liability for the financial year 2022.

Allocation of profit or loss
The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for 2022 and that the results of the company shall be carried forward.

Board of Directors and auditor
The AGM resolved, in accordance with the proposal of a group of shareholders consisting of Per Gerde, Tigerstaden AS and others, on re-election of Fredrik Sjövall, Mikaela Bruhammar and Andreas Pettersson Rohman and election of Per Gerde as board members. Fredrik Sjövall was re-elected as the chairman of the Board of Directors. The AGM re-elected the audit firm Ernst & Young Aktiebolag as auditor.

The AGM further resolved on remuneration to the Board of Directors in accordance with the proposal of a group of shareholders consisting of Per Gerde, Tigerstaden AS and others. The AGM furthermore resolved, in accordance with the above-mentioned shareholders’ proposal, that remuneration to the auditor shall be paid in accordance with approved statement of costs.

Nomination Committee for the next Annual General Meeting
The AGM resolved, in accordance with the proposal of a group of shareholders consisting of Per Gerde, Tigerstaden AS and others, that the principles for appointing the Nomination Committee adopted at the AGM of 2022 shall apply also for the AGM to be held in 2024.

Resolution on issue authorization
The AGM resolved, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to, at one or several occasions and for the period up until the next AGM, resolve to increase the company’s share capital by issuing new shares, convertibles or warrants. Such issue resolution may be carried out with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions. The number of shares that can be issued, or, in case of issuance of convertibles or warrants, added after conversion of exercise, with the support of authorization shall be limited to 30 percent of the number of outstanding shares at the time of this AGM.

The reason for deviating from the shareholders’ pre-emption rights is to increase the Company’s financial flexibility and the Board of Directors’ scope of action. If the Board of Directors decides on an issue deviating from the shareholders’ pre-emption rights, the reason must be to enable widening of the ownership circle, to acquire or enable the acquisition of working capital, to increase the liquidity of the share, to carry out company acquisitions or to acquire or enable the acquisition of capital for company acquisitions.

Incentive program
The AGM resolved, in accordance with the Board of Directors’ proposal, to adopt an incentive program for certain employees and consultants consisting of employee stock options. In short, the incentive program includes an issue of not more than 324 000 employee stock options. The AGM furthermore resolved on an issue of not more than 425 801 warrants to ensure delivery of shares to the participants and to hedge costs connected to the program. Each employee stock option entitles the holder to either acquire one share at a price corresponding to the quota value of the share or to receive, free of charge, a warrant entitling the holder to subscribe for one share in the Company at a subscription price corresponding to the quota value of the share during the period from 1 June 2026 up to and including 30 June 2026.

2023-05-11 Ziccum Strategin ger resultat med betald studie i samarbete med toppbolag: VD-intervju på svenska Pressreleaser Ladda ner | Visa Stäng
2023-05-09 Ziccum Ziccum signs Evaluation Agreement with Biopharmaceutical Corporation focused on mRNA technologies Pressreleaser Ladda ner | Visa Stäng
2023-05-09 Ziccum Ziccums Q1-resultat: VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-05-08 Ziccum KOMPLETTERING TILL KALLELSEN TILL ÅRSSTÄMMA I ZICCUM AB (PUBL), ATT HÅLLAS DEN 24 MAJ 2023, KL. 11.00 I BOLAGETS LOKALER PÅ SCHEELEVÄGEN 22 I LUND Pressreleaser Ladda ner | Visa Stäng
2023-05-02 Ziccum Ziccum AB filing three patent applications as part of new, expanded strategy to strengthen patent protection Pressreleaser Ladda ner | Visa Stäng
2023-04-26 Ziccum ZICCUM AB (publ) releases Interim report Q1 2023 Rapporter Ladda ner | Visa Stäng
2023-04-24 Ziccum KALLELSE TILL ÅRSSTÄMMA I ZICCUM AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-03-20 Ziccum Ziccum reports positive results from drying of active mRNA and promising mRNA activity after powder reconstitution Pressreleaser Ladda ner | Visa Stäng
2023-03-17 Ziccum Ziccum to attend BIO-Europe Spring in Basel Pressreleaser Ladda ner | Visa Stäng
2023-03-10 Ziccum Ziccum AB joins innovative financial platform for Investor Relations management and European outreach Pressreleaser Ladda ner | Visa Stäng
2023-02-17 Ziccum ZICCUM AB (publ) releases Annual Report 2022 Rapporter Ladda ner | Visa Stäng
2023-01-27 Ziccum ZICCUM AB (publ) Year-end report Q4 2022 Analyser Ladda ner | Visa Stäng
2023-01-23 Ziccum Ziccum submits Expression of Interest for CEPI funding Analyser Ladda ner | Visa Stäng
2023-01-18 Ziccum Ziccum CEO to present at international mRNA Summit in Berlin Analyser Ladda ner | Visa Stäng
2022-12-16 Ziccum Ziccum awarded 10 MSEK Eurostars funding for 3D-modeling and Digital twin project Analyser Ladda ner | Visa Stäng
2022-12-14 Ziccum Ziccum launches new, expanded website Analyser Ladda ner | Visa Stäng
2022-12-08 Ziccum Ziccum signs agreement with Zurich University of Applied Sciences on advanced 3D-modeling project Analyser Ladda ner | Visa Stäng
2022-10-28 Ziccum Ziccums Q3-resultat: VD-uppdatering på svenska Analyser Ladda ner | Visa Stäng
2022-10-27 Ziccum ZICCUM AB (publ) Interim report Q3 2022 Analyser Ladda ner | Visa Stäng
2022-10-24 Ziccum Ziccum generates proof of successful drying of lipid nanoparticles in mRNA project Analyser Ladda ner | Visa Stäng
2022-09-27 Ziccum Ziccum reopens application for CEPI funding on thermostable vaccines with new partner Analyser Ladda ner | Visa Stäng
2022-09-23 Ziccum Ziccum receives results from evaluation study with leading Pharmaceutical Corporation Analyser Ladda ner | Visa Stäng
2022-09-14 Ziccum Ziccum and Zurich University of Applied Sciences submit joint application for Eurostars funding Analyser Ladda ner | Visa Stäng
2022-09-01 Ziccum Ziccum on the move: company to attend major industry events across Europe in 2022 Analyser Ladda ner | Visa Stäng
2022-08-23 Ziccum ZICCUM AB (publ) Interim report Q2 2022 Analyser Ladda ner | Visa Stäng

Kommande händelser

29 Apr 2024 | Kvartalsrapport 2024-Q1
17 May 2024 | Årligutdelning
30 Jul 2024 | Kvartalsrapport 2024-Q2
29 Oct 2024 | Kvartalsrapport 2024-Q3
29 Jan 2025 | Bokslutskommuniké 2024